Informação sobre produto
AZP-531 is a drug that has been shown to have pharmacokinetic properties and pharmacodynamics in humans. It has a terminal half-life of about 7 hours, which is shorter than the half-life of most drugs. AZP-531 binds to the myocardium and mesentery and can be used to treat metabolic disorders such as obesity. This drug has also been shown to inhibit protein synthesis in animals, but not humans. The drug was well-tolerated by healthy volunteers with no serious adverse effects reported. AZP-531 is an analog of rapamycin, a macrolide antibiotic that was originally developed for cancer therapy but was found ineffective for this purpose. Rapamycin inhibits cell growth by binding to the immunophilin FKBP12, which prevents the mTOR kinase from associating with its substrate S6K1 and phosphorylating it. AZP-531 may have potential as an anti-cancer agent
Propriedades químicas
Consulta técnica sobre: 3D-NTB54362 AZP-531
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
